Corporate Overview

December 2021

Nasdaq: BIOC

www.biocept.com

2

Forward-Looking Statements

This presentation contains, and any accompanying oral presentation would no doubt contain, forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding Biocept, Inc. and our business. Forward-looking statements include all statements that are not historical facts and generally can be identified by terms such as anticipates, believes, could, estimates, expects, intends, may, plans, potential, predicts, projects, should, will, would, or the negative of those terms and similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For details about these risks, please see our SEC filings.

All forward-looking statements contained in this presentation speak only as of the date hereof, and except as required by law, we assume no obligation to update these forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

3

Corporate Profile

Patented technology used for liquid biopsy in cancer

Providing actionable information to help physicians make treatment decisions

Unique benefit in CNSide™ neuro-oncology testing

CLIA - CAP-accredited laboratory located in San Diego

Target SelectorTM products (kits and tubes) sold to labs worldwide

Collaborations and partnerships with renowned institutions

COVID Strategy to assist in pandemic

4

Corporate Highlights

Biocept is focused on high unmet clinical needs

  • Patients with metastatic cancer involving the central nervous system (CNS) with CNSide assay
  • High-volume,high-serviceCOVID-19 testing for skilled care facilities and institutions
  • Innovative, high-value breast cancer service has gained reimbursement of >$2,000 per assay from Medicare

Biocept is positioned in a $17 billion dollar market1

  • Liquid biopsy for diagnosis, therapy decisions and monitoring in cancer for use by healthcare providers
  • Focus on neuro-oncology and related areas estimated to be a $1B market
  • Collaborations in place with leading academic institutions
  • Quest Diagnostics collaboration for Target Selector™ NGS lung cancer panel
  • Strong balance sheet and growing revenue

Biocept has unique technology to inform clinical decisions

  • Patented dual tumor cell and cell-free DNA testing platforms
  • CLIA, CAP validated laboratory developed tests for testing both cerebrospinal fluid (CSF) and blood
  • Detected biomarkers are listed in NCCN guidelines

1Liquid Biopsy Market Research Report Global Forecast to 2022, Market Research Future

5

Biocept COVID-19 Testing

660,000+ COVID-19 samples received for SARS-CoV-2 Testing since launch in June 2020

  • Average reimbursement of ~$100 per sample
  • Diverse base of business in clinics, skilled nursing and colleges leads to repeat testing per client
  • Fast turnaround times with vast majority of results reported in 48 hours
  • Biocept COVID-19 test is performed with TaqPath™ RT-PCR EUA molecular diagnostic platform
  • Testing performed in high-complexity,CLIA-certified and BSL-2 safety level lab by licensed molecular lab staff trained to perform COVID-19 testing

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Biocept Inc. published this content on 12 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 December 2021 01:25:03 UTC.